Trial · NCT03151551
Results by group68
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 68
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Simultaneously Achieving American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI100) | Ixekizumab | 36 | 95% Confidence Interval 30.4 to 41.6 | percentage of participants | |
| Percentage of Participants Simultaneously Achieving American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI100) | Adalimumab | 27.9 | 95% Confidence Interval 22.7 to 33.1 | percentage of participants | |
| Percentage of Participants Achieving ACR50 | Ixekizumab | 50.5 | 95% Confidence Interval 44.7 to 56.4 | percentage of participants | |
| Percentage of Participants Achieving ACR50 | Adalimumab | 46.6 | 95% Confidence Interval 40.8 to 52.5 | percentage of participants | |
| Percentage of Participants Achieving PASI100 | Ixekizumab | 60.1 | 95% Confidence Interval 54.4 to 65.8 | percentage of participants | |
| Percentage of Participants Achieving PASI100 | Adalimumab | 46.6 | 95% Confidence Interval 40.8 to 52.5 | percentage of participants | |
| Change From Baseline in Tender Joint Count (TJC) | Ixekizumab | -15.91 | Standard Error 0.566 | score on a scale | |
| Change From Baseline in Tender Joint Count (TJC) | Adalimumab | -14.88 | Standard Error 0.569 | score on a scale | |
| Change From Baseline in Swollen Joint Count (SJC) | Ixekizumab | -9.58 | Standard Error 0.196 | score on a scale | |
| Change From Baseline in Swollen Joint Count (SJC) | Adalimumab | -9.53 | Standard Error 0.198 | score on a scale | |
| Change From Baseline in Participant's Assessment of Pain Visual Analogue Score (VAS) | Ixekizumab | -37.21 | Standard Error 1.623 | millimeters (mm) | |
| Change From Baseline in Participant's Assessment of Pain Visual Analogue Score (VAS) | Adalimumab | -36.54 | Standard Error 1.621 | millimeters (mm) | |
| Change From Baseline in Participant's Global Assessment of Disease Activity | Ixekizumab | -40.61 | Standard Error 1.594 | Millimeter (mm) | |
| Change From Baseline in Participant's Global Assessment of Disease Activity | Adalimumab | -37.82 | Standard Error 1.596 | Millimeter (mm) | |
| Change From Baseline in Physician's Global Assessment of Disease Activity | Ixekizumab | -48.15 | Standard Error 1.113 | Millimeter (mm) | |
| Change From Baseline in Physician's Global Assessment of Disease Activity | Adalimumab | -46.79 | Standard Error 1.097 | Millimeter (mm) | |
| Change From Baseline in C-Reactive Protein (CRP) | Ixekizumab | -5.68 | Standard Error 0.462 | Milligram per Liter (mg/L) | |
| Change From Baseline in C-Reactive Protein (CRP) | Adalimumab | -6.01 | Standard Error 0.461 | Milligram per Liter (mg/L) | |
| Change From Baseline in HAQ-DI | Ixekizumab | -0.68 | Standard Error 0.035 | score on a scale | |
| Change From Baseline in HAQ-DI | Adalimumab | -0.62 | Standard Error 0.035 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03151551/results